Global Genomics Group (G3) In Collaboration with Semmelweis University in Budapest, Hungary, Unravel the Heritability of Adiposity, Paving the Way to New Drug Targets in Obesity and Non-Alcoholic Fatty Liver Disease
ATLANTA, Sept. 14, 2017 /PRNewswire/ -- Global Genomics Group (G3), a leading precision-medicine based biopharmaceutical company and Semmelweis University in Budapest, Hungary, today announced that they have uncovered the degree of genetic heritability vs. environmental influences on the deposition of fat in different compartments of the human body. The findings were reported in the International Journal of Obesity, a member of the Nature family of journals, from the BUDAPEST-GLOBAL study, co-lead by Professors Maurovich-Horvat, Jermendy and Merkely from Semmelweis University in Budapest, Hungary, and Szilard Voros, Founder and Chief Executive Officer of Global Genomics Group (Atlanta, GA; USA). The study found that deposition of fat in different body compartments is under strong genetic influence, with epicardial (fat around the heart), subcutaneous (fat under the skin) and visceral adipose tissue (fat around the internal organs) being 80%, 78% and 70% determined by inherited genetic factors. The investigators also found that deposition of fat in the different body compartments is not independent of each other. The findings were derived from a classical twin study of 180 twin subjects from the BUDAPEST-GLOBAL clinical study, and were based on sophisticated analysis of the combined inheritance of complex traits.
"To our knowledge, this is the first study to simultaneously assess the influence of genetic factors of several fat compartments in the human body", said Professor Merkely from Semmelweis University of Budapest, Hungary. "Our findings are very important in the context of the inheritance of body fat, obesity and body weight. In this study, we identified a common factor that drives the development of fat accumulation and obesity, and further detailed studies are required to uncover the here-to-date unidentified driving force behind the deposition of fat in different compartment of our bodies", added Professor Maurovich-Horvat, co-investigator and co-author from Semmelweis University.
"We are delighted that we could contribute to this important study of fat deposition in the human body", said Szilard Voros, Founder and CEO of Global Genomics Group. This study opens the path to identify novel biological pathways and mechanisms of human obesity, a major epidemic plaguing the United States, Europe and the developed world. Studies like this pave the way to identify novel biological pathways and novel, genetically validated drug targets to combat obesity, insulin resistance, metabolic syndrome, diabetes and fatty liver disease. We are currently utilizing Global Genomics Group's comprehensive biological Big Data, combined with novel and visionary artificial intelligence-based analytical tools to further unravel the biology of obesity and to identify new, genetically validated drug targets to combat the epidemic of obesity-related epidemic and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NASH) in the developed world. We have already identified novel, genetically validated drug targets in NASH and we are discussions with several pharmaceutical companies regarding potential clinical development of these novel NASH targets."
About Global Genomics Group (G3)
G3 is the leading precision-medicine-based biopharmaceutical company, developing genetically validated drug targets and novel biomarkers based on biological Big Data, using novel artificial intelligence and machine-learning algorithms and traditional systems-biology-driven bioinformatics approaches to unravel new biologies of common, chronic diseases and rare diseases. G3 combines precision phenotyping with pan-omics (genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics and lipoprotein proteomics) and systems-biology driven bioinformatics to investigate the development and progression of common chronic diseases, as well as rare and orphan diseases.
For additional information, please visit www.globalgenomicsgroup.com
G3 Contact:
Brad Brown, VP of Clinical Affairs
brad.brown@globalgenomicsgroup.com
SOURCE Global Genomics Group
